Gonadotropin-releasing hormone (GnRH) agonists are used for gonadal suppression in the treatment of breast and prostate cancers. In older men, their use has occasionally been associated with cardiovascular side effects such as supraventricular tachyarrhythmias (SVTs). Several reports document their occurrence in men receiving leuprolide for prostate cancer. We now report this complication with ...

Although 3!,5!-cyclic AMP (cAMP) is known to regulate oligodendrocyte development in vitro, little is known about the identity of agonists that induce cAMP synthesis in oligodendroglia. To identify such agonists, we used a novel immunohistochemical method of visualizing cAMP within single cells to screen compounds that are known to activate cAMP synthesis in other cellular systems. Calcitonin, ...

Uterine fibroids are a common disease in women and lead to different symptoms, like pain and bleeding disorders. Apart from surgical treatment, there are many medical treatment options, which are presented in this article. Combined oral contraceptives and Levonorgestrel-releasing intrauterine systems are possible options for bleeding disorders that are a consequence of uterine fibroids. Gonadot...

INTRODUCTION Androgen deprivation therapy (ADT) is the lynchpin of treatment for advanced prostate cancer. Prescribing physicians and patients have a choice between orchiectomy, luteinizing hormone releasing hormone (LHRH) agonists, combined androgen deprivation (CAD) or LHRH antagonists. MATERIALS AND METHODS Literature relating to the use of LHRH antagonists in the management of prostate ca...

Prostate cancer is the second leading cause of cancer-related death among men in the United States.[1] Androgen deprivation therapy (ADT) is a common treatment for prostate cancer. ADT includes gonadotropin-releasing hormone (GnRH) agonists (leuprolide, goserelin, triptorelin), bilateral orchiectomy, and anti-androgen receptor blockers such as flutamide and bicalutamide. Several studies have no...

During the past 25 years, advances in reproductive medicine have led to the development of novel techniques that give cancer patients who are facing impending sterility an opportunity to bear biological offspring. However, the availability and expense of some fertility preservation methods have limited their universality and, therefore, patient access. By contrast, ovarian transposition prior t...

There are few options for treating hormone-refractory prostate cancer (PC). Various studies indicate that luteinizing hormone-releasing hormone (LHRH) agonists may have a direct inhibitory effect on prostate tumors mediated by specific LHRH receptors. One study evaluated LHRH receptors in hormone-dependent PC tissue, but no data have thus far been obtained on the presence of LHRH receptors in b...